Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since May 21 · below the Ichimoku cloud · RSI 31 · MACD above its signal · 8% above its 52-week low
| 6.12 | 52-week high | +632.67% |
| 1.80 | Previous month high | +115.49% |
| 1.05 | Previous week high | +25.70% |
| 1.04 | R3 (classic) | +24.51% |
| 1.01 | Previous month low | +20.91% |
| 0.9800 | R2 (classic) | +17.32% |
| 0.9200 | Previous day high | +10.14% |
| 0.8920 | R1 (classic) | +6.79% |
| 0.8750 | Previous week low | +4.75% |
| 0.8353 | Price now | |
| 0.8320 | Pivot | −0.40% |
| 0.7720 | Previous day low | −7.58% |
| 0.7720 | 52-week low | −7.58% |
| 0.7440 | S1 (classic) | −10.93% |
| 0.6840 | S2 (classic) | −18.11% |
| 0.5960 | S3 (classic) | −28.65% |
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $215.4K | 0.00% | 70.86K | New | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a NMTC trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 26, 2026 | Wambeke David JOfficer | Purchase at price 2.01 per share. | 33.3K | $67.00K |
| Jun 29, 2026 | Christianson MarkOfficer | Sale at price 3.18 per share. | 10K | $31.77K |
| Apr 1, 2026 | Mathiesen Jeffrey SDirector | — | 41.9K | — |
| Apr 1, 2026 | Buckman Paul RDirector | — | 41.9K | — |
| Apr 1, 2026 | Andrle EdwardDirector | — | 41.9K | — |
| Apr 1, 2026 | Mills Jason RichardDirector | — | 41.9K | — |
| Mar 29, 2026 | Christianson MarkOfficer | Sale at price 0.74 per share. | 15.4K | $11.37K |
| Mar 12, 2026 | Christianson MarkOfficer and Director | Sale at price 0.80 per share. | 917 | $734 |
| Mar 10, 2026 | Christianson MarkOfficer | Sale at price 0.80 per share. | 13.7K | $10.98K |
| Feb 26, 2026 | Wambeke David JOfficer | Purchase at price 0.67 per share. | 1.00M | $670.40K |
| Dec 17, 2025 | Mills Jason RichardDirector | — | 7.8K | — |
| Sep 4, 2025 | Christianson MarkOfficer | Sale at price 0.74 per share. | 30K | $22.20K |
| Jun 3, 2025 | Christianson MarkOfficer | Sale at price 0.58 per share. | 10K | $5.80K |
| May 21, 2025 | Christianson MarkOfficer | Sale at price 0.62 - 0.65 per share. | 9K | $5.60K |
| May 19, 2025 | Christianson MarkOfficer | Sale at price 0.66 - 0.67 per share. | 11K | $7.31K |
| Apr 3, 2025 | Rosa David AChief Executive Officer | Purchase at price 0.50 per share. | 100K | $50.00K |
| Apr 3, 2025 | Mcclurg Ronald W.Chief Financial Officer | Purchase at price 0.50 per share. | 200K | $100.00K |
| Feb 13, 2025 | Mathiesen Jeffrey SDirector | — | 27.8K | — |
| Feb 13, 2025 | Buckman Paul RDirector | — | 27.8K | — |
| Feb 13, 2025 | Andrle EdwardDirector | — | 27.8K | — |
TimeframesDown on all 4 timeframes: no timeframe is holding up.
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 16.8 | -24.3 | 16.0 | 0.8 | -24.5 | -14.4 | -44.4 | 0.6 | -39.4 | -18.9 | −81.6% | ||
| 2025 | 39.2 | -3.0 | -23.8 | -26.6 | -2.1 | 11.0 | 15.3 | -2.3 | 16.4 | -10.9 | -12.2 | 9.1 | −8.2% |
| 2024 | -20.9 | -3.2 | -0.8 | -5.8 | -17.7 | -14.0 | -6.3 | 6.1 | 24.4 | -2.0 | -35.8 | 32.6 | −47.7% |
| 2023 | 20.8 | 11.0 | 0.0 | -4.3 | -21.4 | -0.8 | -15.0 | -16.6 | 4.6 | 1.1 | 61.1 | 9.0 | +31.7% |
| 2022 | 0.5 | 2.6 | -45.0 | -30.0 | 48.1 | -28.0 | 43.7 | 116.1 | -33.7 | -42.3 | 44.6 | -14.9 | −38.1% |
| 2021 | 40.1 | 20.5 | -7.5 | -8.2 | 9.5 | -10.3 | -28.4 | -25.3 | 11.3 | -28.6 | -24.1 | -9.4 | −58.8% |
| 2020 | 4.2 | -10.5 | -15.3 | 17.0 | -32.3 | -4.0 | 25.9 | -5.0 | -24.9 | -17.5 | -3.8 | 53.9 | −34.0% |
| 2019 | -10.1 | 20.0 | -31.0 | -4.6 | -15.9 | 5.4 | 5.7 | -36.5 | -20.4 | 7.0 | 86.5 | -36.2 | −57.2% |
| 2018 | 0.5 | 5.5 | -4.7 | 5.2 | 43.2 | -22.4 | 18.8 | 2.9 | 1.1 | +45.9% |
Buy / hold / sell counts
NeuroOne Medical Technologies Corporation, a medical technology company, provides solutions for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording in the United States. The company also provides solutions for spinal cord stimulation, brain stimulation, drug delivery and ablation solutions for patients suffering from epilepsy, trigeminal neuralgia, Parkinson's disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other pain-related neurological disorders. The company has a collaboration with the Department of Neurology's Division of Epilepsy at the University of Minnesota Medical School to advance a study evaluating epilepsy therapies. The company is based in Eden Prairie, Minnesota.